HIV Type 1 Genotypic Resistance in a Clinical Database Correlates with Antiretroviral Utilization

AIDS Research and Human Retroviruses

Volumn 20, Issue 1, 2004, Pages 1-9

  Kagan, Ron ^a   Winters, Mark ^b   Merigan, Thomas ^b   Heseltine, Peter ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ARTICLE; BIOLOGICAL MONITORING; DATA BASE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC CORRELATION; GENOTYPE ENVIRONMENT INTERACTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION RESISTANCE; INFECTION SENSITIVITY; INFORMATION RETRIEVAL; MEDICAL PRACTICE; MUTATIONAL ANALYSIS; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; VIRUS RESISTANCE; VIRUS STRAIN;

ANTI-HIV AGENTS; DATABASES, GENETIC; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0742290185     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922204322749440     Document Type: Article

References (53)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
2. Carpenter CC, Cooper DA, Fischl MA, et al.: Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel. JAMA 2000;283:381-390.
3. Yeni PG, Hammer SM, Carpenter CC, et al.: Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288: 222-235.
4. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al.: Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. JAMA 2000;283: 2417-2426.
5. Richman DD, Bozzette S, Morton S, et al.: The prevalence of antiretroviral drug resistance in the US. Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, IL, abstract LB-17.
6. Boden D, Hurley A, Zhang L, et al.: HIV-1 drug resistance in newly infected individuals. JAMA 1999;22-29;282:1135-1141.
7. Little SJ, Holte S, Routy JP, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
8. Simon V, Vanderhoeven J, Hurley A, et al.: Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002;16:1511-1519.
9. Durant J, Clevenbergh P, Halfon P, et al.: Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. Lancet 1999;353:2195-2199.
10. Clevenbergh P, Durant J, Halfon P, et al.: Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: Week 48 follow-up. Antiviral Ther 2000;5:65-70.
11. Baxter JD, Mayers DL, Wentworth DN, et al.: A randomized study of antiretroviral management based on plasma genotypic anti-retroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000;14:F83-93.
12. DeGruttola V, Dix L, D'Aquila R, et al.: The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Ther 2000;5:41-48.
13. Tural C, Ruiz L, Holtzer C, et al.: Clinical utility of HIV-1 genotyping and expert advice: The Havana trial. AIDS 2002;16: 209-218.
14. Eron J, Bosch RJ, Petch L, et al.: Antiretroviral activity of didanosine in lamivudine-experienced subjects in comparison to activity in subjects who were lamivudine-naive. Antiviral Ther 2002;7(Suppl. 1):102.
15. Pozniak A, Gazzard BG, Peeters M, et al.: Influence of the M184V mutation on virological outcome of highly active anti-retroviral therapy with or without didanosine. Antiviral Ther 2002;7 (Suppl. 1):124.
16. Winters MA, Bosch RJ, Albrecht MA, et al.: Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside-experienced patients. Antiviral Ther 2002;7(Suppl. 1):101.
17. Harrigan PR, Salim M, Stammers DK, et al.: A mutation in the 3′ region of the human immunodeficiency virus type 1 reverse transcriptase associated with nonnucleoside reverse transcriptase inhibitor resistance. J Virol 2002;76:6836-6840.
18. Harrigan PR, Miller MD, McKenna P, et al.: Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 2002;46:1067-1072.
19. Kempf DJ, Isaacson JD, King MS, et al.: Identification of geno typic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001;75:7462-7469.
20. Margot NA, Isaacson E, McGowan I, et al.: Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002;16:1227-1235.
21. Colonno RJ, Friborg J, Rose RE, et al.: Identification of amino acid substitutions correlated with reduced atazanavir susceptibility in patients treated with atazanavir containing regimens. Antiviral Ther 2002;7(Suppl. 1):4.
22. Colonno RJ, Thiry A, and Prkin NT: Amino acid substitutions that correlate with decreased susceptibility to atazanavir and other HIV-1 protease inhibitors. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego, CA, abstract H-2049.
23. Ross L, Liao Q, Gao H, et al.: Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologie response to salvage therapy. AIDS Res Hum Retroviruses 2001;17: 1379-1385.
24. Naeger LK, Margot NA, and Miller MD: ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2002;46:2179-2184.
25. Shafer RW: Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 2002;15:247-277.
26. Whitcomb JM, Paxinos E, Huang W, et al.: The presence of nucleoside analogue mutations is highly correlated with reduced susceptibility to all NRTIs. 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002, Seattle, WA, abstract 569-T.
27. Iversen AK, Shafer RW, Wehrly K, et al.: Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 1996;70:1086-1090.
28. Shafer RW, Winters MA, Iversen AK, et al.: Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors. Antimicrob Agents Chemother 1996;40:2887-2890.
29. Larder BA, Bloor S, Kemp SD, et al.: A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother 1999;43:1961-1967.
30. Winters MA, Coolley KL, Girard YA, et al.: A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 1998;102:1769-1775.
31. Winters MA, Coolley KL, Cheng P, et al.: Genotypic, phenotypic, and modeling studies of a deletion in the beta3-beta4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors. J Virol 2000;74:10707-10713.
32. Kemp SD, Shi C, Bloor S, et al.: A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine. J Virol 1998;72:5093-5098.
33. Gallego O, Corral A, de Mendoza C, et al.: Prevalence of G333D/E in naive and pretreated HIV-infected patients. AIDS Res Hum Retroviruses 2002;18:857-860.
34. Jacobsen H, Yasargil K, Winslow DL, et al.: Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995;206: 527-534.
35. Calvez, V, I. Cohen-Codar AG, Marcelin, D, et al.: Identification of individual mutations in HIV protease associated with virological response to lopinavir/ritonavir therapy. Antiviral Ther 2001;6(Suppl. 1):64.
36. Paulsen D, Liao Q, Fusco G, et al.: Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia. AIDS Res Hum Retroviruses 2002;18:1011-1019.
37. Partaledis JA, Yamaguchi K, Tisdale M, et al.: In vitro selection and characterization of human immunodeficiency virus type 1 isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 1995;69: 5228-5235.
38. Tisdale M, Myers RE, Maschera B, et al.: Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995;39:1704-1710.
39. Condra JH, Schleif WA, Blahy OM, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-571.
40. Palmer S, Shafer RW, and Merigan TC: Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS 1999;13:661-667.
41. Snowden W, Shortino D, Klein A, et al.: Development of amprenavir resistance in NRTI-experienced patients: Alternative mechanisms and correlation with baseline resistance to concomitant NRTIs. Antiviral Ther 2000;5(Suppl. 3):84.
42. Maguire M, Shortino D, Klein A, et al.: Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: Selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob Agents Chemother 2002;46:731-738.
43. Larder BA, Kemp SD, and Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995;269:696-699.
44. Ait-Khaled M, Stone C, Amphlett G, et al.: M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS 2002;16: 1686-1689.
45. Huang W, Wrin T, Gamarnik A, et al.: Reverse transcriptase mutations that confer non-nucleoside reverse transcriptase inhibitor resistance may also impair replication capacity. Antiviral Ther 2002;7(Suppl. 1):60.
46. Koelsch KK, Little S, Ignacio CC, et al.: Diverse outcome of genotypic resistance analysis over time in two patients with transmitted reverse transcriptase inhibitor and protease inhibitor resistance mutations at primary infection. Antiviral Ther 2002;7(Suppl. 1):64.
47. Gallego O, Ruiz L, Vallejo A, et al.: Rate of virological treatment failure and frequencies of drug resistance genotypes among human immunodeficiency virus-positive subjects on antiretroviral therapy in Spain. J Clin Microbiol 2002;40:3865-3866.
48. De Clercq E: Highlights in the development of new antiviral agents. Mini Rev Med Chem 2002;2:163-175.
49. Jiang S, Zhao Q, and Debnath AK: Peptide and non-peptide HIV fusion inhibitors. Curr Pharm Des 2002;8:563-580.
50. Nair V: HIV integrase as a target for antiviral chemotherapy. Rev Med Virol 2002;12:179-193.
51. Andrews L and Friedland G: Progress in HIV therapeutics and the challenges of adherence to antiretroviral therapy. Infect Dis Clin North Am 2000;14:901-928.
52. Lobato RL, Kim EY, Kagan RM, et al.: Genotypic and phenotypic analysis of a novel 15-base insertion occurring between codons 69 and 70 of HIV type 1 reverse transcriptase. AIDS Res Hum Retroviruses 2002;18:733-736.
53. Kim EY, Winters MA, Kagan RM, et al.: Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients J Virol 2001;75: 11227-11233.